Skip to main content
BioCentury
As published for the week of Monday, March 23, 2015


  • Cover Story: Strategy: Show me the value

    How Medicines Co. develops drugs to show both health and economic benefits

    By Emily Cukier-Meisner, Senior Writer

    At a time when industry is struggling mightily with how to demonstrate the value of its products to payers and patients and translate that value into pricing, The Medicines Co. could provide some lessons. The acute care company has been investing since the early 2000s to understand how customers value medicines, and to develop best practices and technology to demonstrate that value.

    Today, the company has integrated these practices into its earliest decisions about what products to develop, and then applies them all the way through to price setting when products reach the market.

    Full Article

Money Raised in 2015

Last week, the biotech industry raised $911 million, bringing to $19.6 billion the total raised year-to-date. In 2014, a total of $54.6 billion was raised, including $21.5 billion in debt, $11.1 billion in follow-ons, $3.9 billion in PIPEs and other equity, $9.1 billion in IPOs, and $9 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.